This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.

Inclusion Criteria:

• 1. The imaging diagnosis is the extensive stage of SCLC
• 2. The patient failed first-line EC+PD-L1 treatment
• 3 PS 0-1

Exclusion Criteria:

• 1. Diagnosed as non-small cell lung cancer
• 2. Women during pregnancy
• 3. Patients with symptomatic brain metastases
• 4. PS≥2